Incidence of pulmonary hemorrhage by histology (REVEL trial)¹

PULMONARY HEMORRHAGE BY HISTOLOGY


Additional adverse events to consider with CYRAMZA as an antiangiogenic therapy2


CLINICALLY RELEVANT ADVERSE EVENTS ASSOCIATED WITH ANTIANGIOGENIC THERAPY



References:
  1. CYRAMZA (ramucirumab) [package insert]. India, Eli Lilly & Company (India) Pvt. Ltd.
  2. Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.Lancet. 2014;384(9944):665-673.
Top